Mario Schlosser Sells 34,120 Shares of Oscar Health (NYSE:OSCR) Stock

Oscar Health, Inc. (NYSE:OSCR) Director Mario Schlosser sold 34,120 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $748,592.80. Following the sale, the director directly owned 480,866 shares of the company’s stock, valued at $10,550,200.04. This represents a 6.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Price Performance

Oscar Health stock opened at $24.59 on Friday. The firm has a market cap of $7.41 billion, a PE ratio of -41.68, a price-to-earnings-growth ratio of 1.65 and a beta of 2.37. Oscar Health, Inc. has a 52-week low of $10.69 and a 52-week high of $25.58. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.26. The company’s 50 day moving average is $18.39 and its two-hundred day moving average is $16.06.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The business had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. During the same period last year, the business earned $0.92 EPS. The company’s revenue was up 52.6% on a year-over-year basis. On average, research analysts expect that Oscar Health, Inc. will post 0.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wall Street Zen cut shares of Oscar Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Robert W. Baird lifted their target price on shares of Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Raymond James Financial upgraded shares of Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a research report on Thursday, February 12th. Jefferies Financial Group upgraded shares of Oscar Health from an “underperform” rating to a “hold” rating and lifted their target price for the stock from $10.00 to $16.00 in a research report on Monday, April 20th. Finally, Zacks Research upgraded shares of Oscar Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.22.

Trending Headlines about Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Wells Fargo upgraded Oscar Health from “strong sell” to “hold”, easing bearish sentiment even though its $20 target remains below the current share price. Zacks.com
• Positive Sentiment: Oscar Health’s recent earnings showed a major EPS beat, which supports the stock’s fundamental story despite revenue coming in below estimates.
• Neutral Sentiment: A company co-founder shifting into an advisory leadership role looks like an internal reorganization rather than a disruptive change. Oscar Health Co-Founder Shifts to Advisory Leadership Role
• Neutral Sentiment: Multiple insiders, including CFO Richard Scott Blackley and CAO Victoria Baltrus, sold shares under pre-planned 10b5-1 programs to cover tax obligations on vested equity awards, which is less concerning than discretionary selling.
• Negative Sentiment: Director Mario Schlosser sold 34,120 shares, the largest insider sale in the latest batch, which may pressure sentiment even though it was pre-arranged.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BIT Capital GmbH boosted its stake in shares of Oscar Health by 545.0% in the fourth quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock valued at $88,897,000 after purchasing an additional 5,227,152 shares during the period. American Century Companies Inc. boosted its stake in shares of Oscar Health by 89.0% in the third quarter. American Century Companies Inc. now owns 5,298,340 shares of the company’s stock valued at $100,298,000 after purchasing an additional 2,495,691 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Oscar Health by 146.5% in the third quarter. Farallon Capital Management LLC now owns 3,639,000 shares of the company’s stock valued at $68,886,000 after purchasing an additional 2,163,000 shares during the period. Morgan Stanley boosted its stake in shares of Oscar Health by 42.8% in the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock valued at $97,918,000 after purchasing an additional 2,043,758 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Oscar Health by 205.1% in the first quarter. Bank of America Corp DE now owns 2,860,310 shares of the company’s stock valued at $32,808,000 after purchasing an additional 1,922,732 shares during the period. 75.70% of the stock is owned by hedge funds and other institutional investors.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.